
Oncology NEWS International
- Oncology NEWS International Vol 16 No 8
- Volume 16
- Issue 8
Taxotere gets fast track status for head and neck cancer indication
Taxotere gets fast track status for head and neck cancer indication
BRIDGEWATER, New JerseySanofi-aventis has received priority review from the FDA for its supplemental New Drug Application for Taxotere (docetaxel) in combination with cisplatin and fluorouracil for induction (neoadjuvant) therapy of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery. The combination is currently approved for induction therapy of inoperable advanced SCCHN. The submission is based on the TAX 324 phase III study showing significantly improved overall survival in patients treated with the Taxotere combination vs cisplatin/fluorouracil alone.
Articles in this issue
almost 19 years ago
Avoiding copay shockalmost 19 years ago
Induction chemo increases survival in unresectable NSCLCalmost 19 years ago
Superselective chemo strategies for HCCalmost 19 years ago
'Value meal dosing' of lapatinib is proposedalmost 19 years ago
AMA approves CPT code for Axxent electronic brachytherapyalmost 19 years ago
Zevalin/R after CHOP-R doubles CRs in follicular NHLalmost 19 years ago
RT plus local paclitaxel gel promising in esophageal caalmost 19 years ago
GeneSearch BLN Assay gets FDA approval for node assessment during surgeryalmost 19 years ago
TH vs TCH in metastatic breast cancer: 'Take your pick'



























































